Initial Safety and Feasibility Results From a Phase 1, Diagnose-and-Treat Trial of Neoadjuvant Intratumoral Cisplatin for Stage IV NSCLC

Initial Safety and Feasibility Results From a Phase 1, Diagnose-and-Treat Trial of Neoadjuvant Intratumoral Cisplatin for Stage IV NSCLC

Neoadjuvant intratumoral cisplatin has the potential to generate substantial cytotoxicity and immune priming within the tumor environment, while minimizing systemic, off-target, adverse events. We initiated a phase 1A, 3+3 dose-ranging study of neoadjuvant, intratumoral cisplatin, delivered through...

Full description

Bibliographic Details
Main Authors: Farrah B. Khan, MD, Pamela C. Gibson, MD, Scott Anderson, MD, Sarah Wagner, BS, Bernard F. Cole, PhD, Peter Kaufman, MD, C. Matthew Kinsey, MD, MPH
Format: Article
Language:English
Published: Elsevier 2024-03-01
Series:JTO Clinical and Research Reports
Subjects:
Intratumoral therapy
Cisplatin
Endobronchial ultrasound-guided transbronchial needle injection
Lung cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364324000043

Internet

http://www.sciencedirect.com/science/article/pii/S2666364324000043

Similar Items